
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*

TELA Bio, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

872381108

(CUSIP Number)

11/17/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 872381108

Names of Reporting Persons

1

EW HEALTHCARE PARTNERS FUND 2, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

- (a)
 (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power
5	3,031,617.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	3,031,617.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	3,031,617.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	6.81 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No. 872381108

1	Names of Reporting Persons
	EW HEALTHCARE PARTNERS FUND 2-A, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	4,683,092.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	4,683,092.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	4,683,092.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>

11 Percent of class represented by amount in row (9)
11 10.52 %
Type of Reporting Person (See Instructions)
12
12 PN

SCHEDULE 13G

CUSIP No. 872381108

Names of Reporting Persons

1
EW Healthcare Partners Fund 2 GP, L.P.
Check the appropriate box if a member of a Group (see instructions)

2
 (a)
 (b)

3 Sec Use Only
Citizenship or Place of Organization

4
DELAWARE

Sole Voting Power
5
7,714,709.00
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
6 Shared Voting Power
0.00
7 Sole Dispositive Power
7,714,709.00
8 Shared Dispositive
Power
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9
7,714,709.00
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11
17.32 %
Type of Reporting Person (See Instructions)
12
12 PN

SCHEDULE 13G

CUSIP No. 872381108

Names of Reporting Persons

1
EW Healthcare Partners Fund 2-UGP, LLC
2
Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5

7,714,709.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6

0.00

Sole Dispositive Power

7

7,714,709.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

7,714,709.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

17.32 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

TELA Bio, Inc.

Address of issuer's principal executive offices:

(b)

1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania, 19355

Item 2.

Name of person filing:

(a)

This Amendment No. 2 to Schedule 13G is being filed jointly by EW Healthcare Partners Fund 2, L.P., a Delaware limited partnership ("EWHP2"), EW Healthcare Partners Fund 2-A, L.P., a Delaware limited partnership ("EWHP2-A"), EW Healthcare Partners Fund 2-GP, L.P., a Delaware limited partnership ("EWHP2 GP"), and EW Healthcare Partners Fund 2-UGP, LLC, a Delaware limited liability company ("EWHP2 General Partner" and collectively with EWHP2, EWHP2-A and EWHP2 GP, the "Reporting Persons"), and relates to shares of common stock, par value \$0.001 per share ("Common Stock"), of TELA Bio, Inc. (the "Issuer").

Address or principal business office or, if none, residence:

(b)

The address of the principal business office of each of the Reporting Persons is 21 Waterway Avenue, Suite 150, The Woodlands, Texas 77380.

Citizenship:

(c)

Each of EWHP2, EWHP2-A, and EWHP2 GP is a Delaware limited partnership. EWHP2 General Partner is a Delaware limited liability company.

Title of class of securities:

(d)

Common Stock, par value \$0.001 per share

(e) CUSIP No.:

872381108

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person. The managers of EWHP2 General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman and Petri Vainio (collectively, the "Managers"). The Managers may exercise voting and investment control over the shares of Common Stock only by majority action of the Managers. Each individual Manager disclaims beneficial ownership over the shares of Common Stock except to the extent of his respective pecuniary interest therein.

Percent of class:

(b) The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person. The percentages set forth herein are calculated based on an aggregate 44,530,535 shares of Common Stock outstanding as of November 17, 2025, which is based on (i) 40,341,535 shares of Common Stock outstanding as of November 3, 2025, as reported in the Issuer's Quarterly Report for the quarter ended September 30, 2025, filed with the U.S. Securities and Exchange Commission on November 14, 2025, and (ii) 4,189,000 shares of Common Stock issued in connection with the Issuer's underwritten registered direct offering, which closed on November 17, 2025. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

(ii) Shared power to vote or to direct the vote:

The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

(iii) Sole power to dispose or to direct the disposition of:

The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

(iv) Shared power to dispose or to direct the disposition of:

The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
- Item 8. Identification and Classification of Members of the Group.
Not Applicable
- Item 9. Notice of Dissolution of Group.
Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EW HEALTHCARE PARTNERS FUND 2, L.P.

Signature: /s/ Martin P. Sutter
Name/Title: Martin P. Sutter, Manager
Date: 11/17/2025

EW HEALTHCARE PARTNERS FUND 2-A, L.P.

Signature: /s/ Martin P. Sutter
Name/Title: Martin P. Sutter, Manager
Date: 11/17/2025

EW Healthcare Partners Fund 2 GP, L.P.

Signature: /s/ Martin P. Sutter
Name/Title: Martin P. Sutter, Manager
Date: 11/17/2025

EW Healthcare Partners Fund 2-UGP, LLC

Signature: /s/ Martin P. Sutter
Name/Title: Martin P. Sutter, Manager
Date: 11/17/2025

Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

JOINT FILING AGREEMENT

Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Common Stock of TELA Bio, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and (iii) the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934 apply to each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G/A as to any of the undersigned upon such person giving written notice thereof to each of the other persons signature hereto, at the principal office thereof.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Date: November 17, 2025

EW HEALTHCARE PARTNERS FUND 2, L.P.

By: /s/ Martin P. Sutter
Name: Martin P. Sutter
Title: Manager

EW HEALTHCARE PARTNERS FUND 2-A, L.P.

By: /s/ Martin P. Sutter
Name: Martin P. Sutter
Title: Manager

EW HEALTHCARE PARTNERS FUND 2-UGP, LLC

By: /s/ Martin P. Sutter
Name: Martin P. Sutter
Title: Manager

EW HEALTHCARE PARTNERS FUND 2 GP, L.P.

By: /s/ Martin P. Sutter
Name: Martin P. Sutter
Title: Manager